Japanese Journal of Cancer and Chemotherapy最新文献

筛选
英文 中文
[A Case of Rectal Cancer with Lateral Lymph Node, Liver and Lung Metastases after Surgery, Successfully Undergoing Radical Resection with Multidisciplinary Treatment]. [直肠癌术后伴侧淋巴结、肝、肺转移1例,经多学科治疗根治性切除成功]。
Yuji Ando, Masaya Kawai, Yuta Murai, Saki Kochi, Miyuki Toake, Hiromitsu Takahashi, Takahiro Irie, Hirotaka Momose, Yuki Tsuchiya, Kota Amemiya, Ryoichi Tsukamoto, Kumpei Honjo, Shun Ishiyama, Kiichi Sugimoto, Kazuhiro Sakamoto
{"title":"[A Case of Rectal Cancer with Lateral Lymph Node, Liver and Lung Metastases after Surgery, Successfully Undergoing Radical Resection with Multidisciplinary Treatment].","authors":"Yuji Ando, Masaya Kawai, Yuta Murai, Saki Kochi, Miyuki Toake, Hiromitsu Takahashi, Takahiro Irie, Hirotaka Momose, Yuki Tsuchiya, Kota Amemiya, Ryoichi Tsukamoto, Kumpei Honjo, Shun Ishiyama, Kiichi Sugimoto, Kazuhiro Sakamoto","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The patient is a 50s-year-old man. He had a past history of familial adenomatous polyposis(FAP)and was diagnosed with hereditary multiple colorectal cancer(RS, Rb). Therefore, he underwent total colectomy with ileostomy. Six months after surgery, right lateral lymph node metastasis, liver metastasis, and bilateral lung metastasis were pointed out, so 5 courses of CAPOX+bevacizumab(Bmab)were subsequently administered. Since the patient was evaluated as a partial response(PR)on CT and PET-CT after chemotherapy, laparoscopic right lateral lymph node dissection, open partial hepatectomy, and robot-assisted partial lung resection were performed on each metastatic lesion at each 2 months intervals. He has no recurrence for 6 months since last surgery.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 4","pages":"336-338"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144021977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Investigation of Preoperative Chemotherapy Using Enterostomy for Advanced Gastric Cancer with Stenosis]. 进展期胃癌伴狭窄的肠造口术前化疗的探讨
Hidetaka A Ono, Yohei Ota, Hirokazu Suwa, Kazunori Nojiri, Kenichi Yoshida, Hidenobu Masui, Kaoru Nagahori
{"title":"[Investigation of Preoperative Chemotherapy Using Enterostomy for Advanced Gastric Cancer with Stenosis].","authors":"Hidetaka A Ono, Yohei Ota, Hirokazu Suwa, Kazunori Nojiri, Kenichi Yoshida, Hidenobu Masui, Kaoru Nagahori","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Preoperative chemotherapy for gastric cancer with obstructive symptoms traditionally requires bypass surgery.</p><p><strong>Objective: </strong>To investigate the feasibility of preoperative enterostomy chemotherapy in patients with advanced gastric cancer who present with obstructive symptoms.</p><p><strong>Methods: </strong>A total of 47 patients with cStage Ⅲ gastric cancer who underwent preoperative chemotherapy between April 2013 and May 2024 were included. Patients with circumferential lesions underwent enterostomy during diagnostic laparoscopy, which was followed by chemotherapy.</p><p><strong>Results: </strong>The enterostomy and non-enterostomy groups included 20 and 27 patients, respectively. The chemotherapy regimens included SOX, SOX+nivolumab, SP, biweekly NAC-DCS, and XP+trastuzumab. Grade 3 or higher adverse events, including neutropenia, malaise, and diarrhea, were more common in the no-enterostomy group. The completion rates of at least 2 chemotherapy courses were similar between groups. Grade Ⅲa or higher complications during gastrectomy were slightly higher in the enterostomy group. The pathological responses were comparable between groups.</p><p><strong>Conclusion: </strong>Preoperative chemotherapy using enterostomy for advanced gastric cancer with obstructive symptoms showed efficacy and safety comparable to those of traditional methods, suggesting that it is a viable treatment option.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 4","pages":"363-365"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144030687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[A Case of cy1 Advanced Gastric Cancer That Achieved CR after Chemotherapy Via an Enterostomy]. [1例cy1晚期胃癌经肠造口化疗后达到CR]。
Hidetaka A Ono, Yohei Ota, Hirokazu Suwa, Kazunori Nojiri, Kenichi Yoshida, Hidenobu Masui, Kaoru Nagahori
{"title":"[A Case of cy1 Advanced Gastric Cancer That Achieved CR after Chemotherapy Via an Enterostomy].","authors":"Hidetaka A Ono, Yohei Ota, Hirokazu Suwa, Kazunori Nojiri, Kenichi Yoshida, Hidenobu Masui, Kaoru Nagahori","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A 67-year-old male presented with severe epigastric pain in May 2023 and was diagnosed with Stage Ⅲ advanced gastric cancer(cStage Ⅲ)in June. Due to indistinct boundaries between lymph node #8a and the pancreas, non-resectional chemotherapy and enterostomy were performed during a diagnostic laparotomy. The diagnosis was updated to sStage Ⅳ with cy1. Beginning in July, the patient was administered SOX and nivolumab. Following 6 courses, CT scans in December revealed clearer boundaries, allowing for conversion surgery in January 2024. This surgery resulted in a pathological complete response(pCR), with no detectable malignant cells. Despite postoperative complications, the patient was discharged on day 34 and is currently receiving outpatient S-1 therapy. This case suggests that enterostomy may facilitate conversion surgery to achieve pCR, thereby providing a new treatment strategy for advanced gastric cancer.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 4","pages":"360-362"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Microphysiological System(MPS)for Drug Research, the Current Situation and the Future]. 微生理系统(MPS)在药物研究中的应用现状与未来
Osamu Ando, Yuzuru Ito
{"title":"[Microphysiological System(MPS)for Drug Research, the Current Situation and the Future].","authors":"Osamu Ando, Yuzuru Ito","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The development of new in vitro cell culture systems, the microphysiological systems(MPSs), is progressing rapidly around the world. MPS is a biomimetic cell culture system that recapitulate tissue biology(patho)physiologically using clinically derived specimens, organoids, or differentiated cells from stem cells on a culture device with circulation and detection devices. New disease model systems are being constructed using MPS and are used as proof-of-concept and drug evaluation systems, and are attracting attention as an approach to addressing unmet medical needs. In conventional anti-cancer drug research, in vitro culture systems are mainly used to evaluate the growth inhibitory potential of cancer cell line monocultures. On the other hand, MPS has made it possible to monitor cancer pathology, malignant traits, and pharmacological activity, such as reproduction of the cancer niche, interactions between cancer cells and various stroma in the tumor microenvironment, cancer cell movement, and immune cell accumulation in cancer tissue. MPS is also used to evaluate safety and adverse effects and pharmacokinetics, which are essential for anticancer drug development. Various MPSs have been developed and reported for these purposes also in Japan, MPS technology is being developed, including for use in the regulatory process for non-clinical studies. Through these efforts, it is expected to lead to innovation in drug discovery in the field of oncology.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 4","pages":"287-293"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Robot-Assisted Resection for Ascending Colon Cancer with a Tumor Thrombus in the Superior Mesenteric Vein after Neoadjuvant Chemotherapy-A Case of Report]. 【机器人辅助切除新辅助化疗后肠系膜上静脉肿瘤血栓一例】。
Takahiro Ishii, Takatoshi Matsuyama, Satoshi Hatano, Noriyasu Chika, Takehiro Shiraishi, Aoi Sugino, Hiroyasu Ishikawa, Toshifumi Saito, Norimichi Chiyonobu, Tetsuya Ito, Yoshiko Mori, Toru Ishiguro, Yoichi Kumagai, Hideyuki Ishida
{"title":"[Robot-Assisted Resection for Ascending Colon Cancer with a Tumor Thrombus in the Superior Mesenteric Vein after Neoadjuvant Chemotherapy-A Case of Report].","authors":"Takahiro Ishii, Takatoshi Matsuyama, Satoshi Hatano, Noriyasu Chika, Takehiro Shiraishi, Aoi Sugino, Hiroyasu Ishikawa, Toshifumi Saito, Norimichi Chiyonobu, Tetsuya Ito, Yoshiko Mori, Toru Ishiguro, Yoichi Kumagai, Hideyuki Ishida","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>An 81-year-old woman visited our hospital for severe anemia and was diagnosed with ascending colon cancer with a tumor thrombus in the superior mesenteric vein(SMV). After 8 courses of mFOLFOX6+bevacizumab therapy followed by 7 courses of fluorouracil and leucovorin+bevacizumab therapy, the primary lesion and tumor thrombus were found to be shrinkage. Then we performed robot-assisted right hemicolectomy and resection of SMV involving the tumor thrombus. The patient was discharged on postoperative day 19. Histological findings revealed residual tumor thrombus in the SMV. The patient is currently under observation at 4 months postoperatively without adjuvant chemotherapy.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 4","pages":"326-328"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143986202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[A Therapeutic Strategy Targeting Virus-Antigen in Cancer Treatment]. 一种针对病毒抗原的肿瘤治疗策略
Tomohiro Enokida
{"title":"[A Therapeutic Strategy Targeting Virus-Antigen in Cancer Treatment].","authors":"Tomohiro Enokida","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Evidence has increasingly highlighted the potential of viral antigens as ideal treatment targets for virus-related cancers, primarily due to their exclusive expression on cancer cells and capacity to stimulate robust immune responses and eliminate malignant cells effectively. Innovative approaches such as vaccines tailored to stimulate an immune response, engineered T-cell therapies designed to evidently recognize and destroy cancer cells, and drug delivery methods for selectively expanding and activating virus-antigen-specific T-cells have shown great promise. Numerous studies have indicated that these virus-targeted therapies have potentially improved patient prognostic outcomes with acceptable toxicities. Future research is essential to optimize these approaches and lead them to clinical practice to achieve complete eradication of virus-related cancers.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 4","pages":"294-299"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144001878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[A Case of Pulmonary Tuberculosis Developed During Neoadjuvant Chemotherapy for HER2-Enriched Breast Cancer]. 【her2富集型乳腺癌新辅助化疗中发生肺结核1例】。
Yoko Mizuyama, Tsutomu Takashima
{"title":"[A Case of Pulmonary Tuberculosis Developed During Neoadjuvant Chemotherapy for HER2-Enriched Breast Cancer].","authors":"Yoko Mizuyama, Tsutomu Takashima","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In the 1990s, the number of newly registered tuberculosis patients in Japan was about 40,000 per year. It has been gradually decreasing and the number of new patients became 10,235 in 2022 with the incidence rate of 8.2 per 100,000 population. However it is still occasionally encountered even in recent years. Herein, we report a case of human epidermal growth factor receptor 2(HER2)-enriched breast cancer patient developed pulmonary tuberculosis just after finishing neoadjuvant chemotherapy and was successfully treated for both disease simultaneously. A 68 years old woman presented due to right breast mass was diagnosed with hormonal receptor-negative, HER2-positive invasive ductal carcinoma. Neoadjuvant chemotherapy with paclitaxel, trastuzumab and pertuzumab was started. After 12 courses of chemotherapy, CT scan revealed disappearance of the right breast tumor and infiltrating shadow in the left lower lung field. Sputum polymerase chain reaction test for tuberculosis was positive. Anti-tuberculosis chemotherapy was started. Four days after starting isoniazid, partial mastectomy was performed under local anesthesia and radiation therapy for the breast was omitted. There are no signs of recurrence of breast cancer and pulmonary tuberculosis for 5 years. Chemotherapy for breast cancer and premedication with corticosteroid may have inhibited cellular immunity, causing endogenous relapse of tuberculosis.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"252-254"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Partial Nephrectomy and Focal Therapy in Small Renal Tumors]. [小肾肿瘤的肾部分切除术和病灶治疗]。
Yoshiyuki Matsui
{"title":"[Partial Nephrectomy and Focal Therapy in Small Renal Tumors].","authors":"Yoshiyuki Matsui","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>With the increasing use of robot-assisted surgery, partial nephrectomy is recommended for small renal tumors(T1a)with a tumor size of 4 cm or less and is now considered a standard treatment. However, with the rise in incidental detection of small renal tumors during routine screenings, especially in elderly patients or those with comorbidities who may hesitate to undergo general anesthesia, there is a growing need for alternative treatments such as focal therapy to partial nephrectomy. The main methods of focal therapy include ablation techniques such as cryotherapy and radiofrequency ablation. Recently, stereotactic body radiotherapy has also been approved for insurance coverage, emerging as a minimally invasive option for renal cell carcinoma with a tumor size of 5 cm or less. Additionally, although not a focal therapy, active surveillance is also considered an effective option for very small renal tumors. Among these various treatment options, shared decision making between patients and healthcare providers, considering factors such as tumor characteristics and patient-specific conditions, is considered crucial in determining the appropriate treatment strategy for small renal tumors. In the absence of large-scale prospective comparative trials on partial nephrectomy, ablation therapy, stereotactic radiotherapy, and active surveillance, this paper provides an overview of the characteristics of each treatment modality and their respective outcomes and discusses the future perspectives in the treatment of small renal tumors.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"205-209"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[A Case of an Older Patient with MSI-High Colorectal Cancer with Distant Lymph Node Metastasis Successfully Treated with Pembrolizumab]. [彭博利珠单抗成功治疗一例 MSI 高、伴有远处淋巴结转移的老年结直肠癌患者】。]
Shintaro Takeda, Yasushi Yoshida, Tomoaki Noritomi, Jun Yanagisawa, Mitsuaki Morimoto, Hiroki Ureshino, Shuhei Ito, Fuminori Ishii, Kazune Komiya, Yasuhito Hosoda, Ren Nakamura, Kyohei Sakamoto, Yutaro Nakagawa, Kozue Nakahara
{"title":"[A Case of an Older Patient with MSI-High Colorectal Cancer with Distant Lymph Node Metastasis Successfully Treated with Pembrolizumab].","authors":"Shintaro Takeda, Yasushi Yoshida, Tomoaki Noritomi, Jun Yanagisawa, Mitsuaki Morimoto, Hiroki Ureshino, Shuhei Ito, Fuminori Ishii, Kazune Komiya, Yasuhito Hosoda, Ren Nakamura, Kyohei Sakamoto, Yutaro Nakagawa, Kozue Nakahara","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The patient was a 90-year-old man with a PS score of 0 and no underlying disease. He visited our hospital with a fever and was diagnosed with cancer of the ascending colon with abscess formation due to retroperitoneal perforation. First, he underwent ileostomy with double orifices and abscess puncture drainage, followed by right semicolon resection plus ileostomy closure to resect the primary tumor. Three months after the surgery, metastases were found in the left cervical supraclavicular and periaortic lymph nodes. The primary tumor was a poorly differentiated adenocarcinoma, RAS wild, BRAF mutation(+), and MSI-high(+). Therefore, pembrolizumab therapy was initiated, which resulted in a complete response(CR) at the end of 6 courses. After 2 years of pembrolizumab treatment, the patient's CR status was maintained, with only Grade 1 hypothyroidism. We believe that pembrolizumab therapy for MSI-high, unresectable, advanced, recurrent colorectal cancer is useful in older patients with good PS, no major underlying disease, and a medical system that can respond to irAE.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"258-259"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Resection of Oligometastasis Liver Metastases from Breast Cancer-Two-Case Report]. [乳腺癌寡转移肝转移灶切除术--两例报告]。
Yusuke Nishio, Satoshi Matsukuma, Shigeru Yamamoto, Masaki Iwado, Hiroaki Yamatani, Daiki Haraguchi, Atomu Suzuki, Naohiro Yamamoto, Sota Yoshimine, Kazuhisa Tokuno, Toru Kawaoka, Hisashi Sakano, Yuji Fujita, Norio Akiyama
{"title":"[Resection of Oligometastasis Liver Metastases from Breast Cancer-Two-Case Report].","authors":"Yusuke Nishio, Satoshi Matsukuma, Shigeru Yamamoto, Masaki Iwado, Hiroaki Yamatani, Daiki Haraguchi, Atomu Suzuki, Naohiro Yamamoto, Sota Yoshimine, Kazuhisa Tokuno, Toru Kawaoka, Hisashi Sakano, Yuji Fujita, Norio Akiyama","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Resection of liver metastases from breast cancer is not widely accepted because the survival benefit of surgery has not been demonstrated. We report the cases of 2 patients who underwent resection of liver metastases from breast cancer. Case 1: This was a female patient in her 50s with synchronous metastasis of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Resection was performed since the patient had exhausted all anti-HER2 therapies and had only a single liver metastasis. Immunohistochemical staining results of the resected specimens showed HER2 negativity. The patient had no recurrence 5 months postoperatively and received adjuvant chemotherapy with capecitabine. Case 2: This was a female patient in her 70s with metachronous metastasis of hormone receptor-positive disease. A single liver metastasis occurred 28 years after the primary tumor resection. During the 2-year hormone therapy, no new lesions appeared, and the tumor was stable; therefore, resection was performed. The resected specimen showed a complete pathological response. Furthermore, the patient has been recurrence-free for 1 year without any therapy.</p>","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 3","pages":"260-262"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信